Literature DB >> 1602558

Role of the fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2.

K R Steffy1, G Kraus, D J Looney, F Wong-Staal.   

Abstract

Syncytium induction is a characteristic feature of infection by human immunodeficiency virus (HIV) in vitro. The hydrophobic amino terminus of the transmembrane glycoprotein of HIV type 1 is an essential determinant of virus entry into the target cell population and the formation of syncytia in cell culture. To define the role of the HIV type 2 fusion peptide during infection and syncytium formation, we introduced 8 amino acid substitutions into the hydrophobic amino terminus of gp41, changing either the hydrophobicity, the charge, or the polarity of the amino acid. Viruses containing the envelope mutations were analyzed for their syncytium-inducing capacities, levels of infectivity, and envelope processing and expression. Mutations that increased the hydrophobic nature of the fusion peptide increased syncytium formation, whereas mutations which increased the charge and the polarity and/or decreased the hydrophobicity of the fusion domain severely reduced the capacity of the virus to induce syncytia. However, viruses severely compromised for syncytium formation exhibit only slightly lower levels of infectivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1602558      PMCID: PMC241263     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

Review 1.  The biochemistry of AIDS.

Authors:  Y N Vaishnav; F Wong-Staal
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

2.  Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.

Authors:  E O Freed; D J Myers; R Risser
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

3.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus.

Authors:  S Chakrabarti; T Mizukami; G Franchini; B Moss
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

5.  Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus.

Authors:  W R Gallaher
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

6.  Demonstration of two distinct cytopathic effects with syncytium formation-defective human immunodeficiency virus type 1 mutants.

Authors:  D Dedera; L Ratner
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Functional contribution of cysteine residues to the human immunodeficiency virus type 1 envelope.

Authors:  E Tschachler; H Buchow; R C Gallo; M S Reitz
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

8.  Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein.

Authors:  M Kowalski; L Bergeron; T Dorfman; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Sequence similarities between human immunodeficiency virus gp41 and paramyxovirus fusion proteins.

Authors:  F Gonzalez-Scarano; M N Waxham; A M Ross; J A Hoxie
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

10.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

View more
  13 in total

1.  The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.

Authors:  A R Rosenberg; L Delamarre; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Entry of duck hepatitis B virus into primary duck liver and kidney cells after discovery of a fusogenic region within the large surface protein.

Authors:  Claudia Maenz; Shau-Feng Chang; Alicja Iwanski; Michael Bruns
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

3.  Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41.

Authors:  M Caffrey; M Cai; J Kaufman; S J Stahl; P T Wingfield; D G Covell; A M Gronenborn; G M Clore
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

4.  HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.

Authors:  Dirk Eggink; Steven W de Taeye; Ilja Bontjer; Per Johan Klasse; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.

Authors:  Welkin E Johnson; Jennifer Morgan; Julie Reitter; Bridget A Puffer; Susan Czajak; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 6.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

7.  Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation.

Authors:  G Alkhatib; J Roder; C Richardson; D Briedis; R Weinberg; D Smith; J Taylor; E Paoletti; S H Shen
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

8.  Transdominant inhibition of wild-type human immunodeficiency virus type 2 replication by an envelope deletion mutant.

Authors:  K R Steffy; F Wong-Staal
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain.

Authors:  S W Barnett; M Quiroga; A Werner; D Dina; J A Levy
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

10.  Amino acid changes in the fourth conserved region of human immunodeficiency virus type 2 strain HIV-2ROD envelope glycoprotein modulate fusion.

Authors:  R Keller; K Peden; S Paulous; L Montagnier; A Cordonnier
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.